TCR2 Therapeutics Inc. (Nasdaq: TCRR), the stock surged higher in the after-market session as it was up 33.36% to $43.6. As a clinical-stage immunotherapy company with a pipeline of novel T cell-based therapies for cancer patients, we revealed today positive interim results from the Phase 1 portion of the TC-210 Phase 1/2 clinical trial.
In the first eight patients treated on the study, three PRs have been achieved based on RECIST 1.1 criteria by the November 24, 2020 data cutoff, with our very first patient had achieved a confirmed PR up to month six.
Furthermore, the first patient-administered at a higher dose of gave-cel (1×108/m2) without lymphodepletion had a stable condition within two months without any noticeable toxicity, enabling patients to resume therapy with the addition of lymphodepletion at that dose.
The toxicology profile remains manageable, with only two patients reporting gavo-cel-related non-hematological grade >2 toxicity to date and no indication of neurotoxicity or on-target, off-tumor side effects. In all patients, translational data demonstrated the expansion of TRuC-T cells and the induction of cytokines.
